The SURPASS 1 through 5 studies were phase 3 clinical trials in which researchers compared the efficacy of 5, 10, or 15 mg tirzepatide with placebo, 1 mg semaglutide, insulin degludec, or insulin ...

At the center of their discovery is a protein called S100A9, which has been shown to reduce dangerous levels of ketones in the blood—without relying on insulin. For people living with type 1 ...

An international expert panel has recently released a comprehensive set of recommendations for optimal insulin injection techniques and equipment. The group, called the Forum for Injection ...

Insulin pumps are wearable devices that people with diabetes use to deliver insulin. They are connected to a spot on your body and continuously give insulin for 2 to 4 days. An insulin pump is a ...

Prescriptions for the insulin glargine biosimilar Semglee increased after it was granted interchangeable status with its reference product, Lantus. Increases were seen across retail, mail order ...

A Japanese hospital said Monday it has completed a clinical test to transplant induced pluripotent stem cells that produce insulin to treat a patient with type 1 diabetes, in a step that could ease ...

while insulin glargine and insulin degludec have side effects that mean some patients are unable to take them. Novo Nordisk has been selling Levemir in the US for nearly 20 years, and in March ...

Insulin is a hormone made in your pancreas, a gland located behind the stomach. It allows your body to use glucose for energy. Glucose is a type of sugar found in many carbohydrates. The body ...

Eli Lilly’s big-selling insulin, Humalog, faces cut-price competition after the US regulator approved a biosimilar from Sanofi. Sanofi’s Admelog (insulin lispro) is approved in type 1 and type ...